Year: 2022
Type: book-chapter
Abstract: There is good evidence that targeting the beta cell could be an important component to developing the future of diabetes therapeutics. In this chapter, the authors review the principles of chemical biology that enable small-molecule discovery, the current state of the art for therapeutic approaches, novel beta cell-focused approaches to use small molecules that improve phenotypes, and more recent efforts to deliver therapeutics selectively to the beta cell.
Institutions: Broad Institute, Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4296503216